Kornimate/medical-research-clean huggingface dataset:
patient-specific computational walking models in improving surgical and rehabilitation treatment in patients with pelvic sarcomas

Conditions: Pelvic Sarcoma

Summary: this trial studies the development of patient-specific computational walking models to improve the surgical planning and rehabilitation treatment of patients with pelvic sarcomas. every pelvis and pelvic sarcoma are different, and the orthopedic oncologist faces significant challenges when removing a tumor from the complex anatomy of the pelvis. these challenges make it difficult to achieve excellent oncological and functional outcomes together. computational walking models may be used to predict the best combination of surgical methods and how to implement them to maximize each patient's post-surgery walking function.

primary objectives: i. to develop patient-specific computational walking models to predict the optimal combination of pelvic sarcoma surgical and rehabilitation decisions that will maximize each patient's post-surgery walking function. ii. to collect experimental movement and imaging data prospectively and retrospectively from individuals who have already received, or are going to receive, a type i or type ii hemipelvectomy. iii. to use the data to develop computational modeling and simulation methodologies that can predict an individual patient's post-surgery walking function given pre-surgery movement and imaging data and the surgical decisions made by the surgeon. outline: patients undergo walking function assessment using optical motion capture and bi-plane dynamic x-ray imaging pre- and post-hemipelvectomy.

Eligibility criteria:
inclusion criteria: 1. patients who have received or are scheduled to receive an internal hemipelvectomy with or without reconstruction at ut md anderson cancer center. 2. patients who are 18 years of age and older exclusion criteria: 1. patients who have undergone an external (hindquarter amputated), or an isolated type iii internal hemipelvectomy. 2. previous surgery or significant injury to either hip (prospective patients only) 3. relevant surgery, procedure, injury, or condition in the last two years which may affect hip pain or general movement patterns on either side (prospective patients only) 4. pregnant women or women nursing an infant 5. persons with a pacemaker, hearing aid, aneurysm clips or artificial heart valves, and other forms of loose metal implants will be excluded from the study as assessed by a pre-mri questionnaire administered by the mri technician at the time of the scan. 6. radiological exclusion criteria (assessed after mr scan is conducted on the first visit, prior to dsx/ct radiation exposure): evidence on preliminary mri of fracture, slipped capital femoral epiphysis (scfe), masses, lesions, or other anomalies not consistent with an fai diagnosis.
nailfold capillaroscopic assessment in pediatric uveitis patients

Conditions: Uveitis

Summary: pediatric uveitis accounts for 5-10% of uveitis cases. it may be infectious or noninfectious in etiology. the etiology of noninfectious uveitis may be autoimmune. the most common causes of pediatric uveitis are idiopathic and juvenile idiopathic arthritis-associated uveitis. uveitis morbidities in pediatric patients include cataract, glaucoma, and amblyopia. pediatric uveitis may be accopanied by involvement of the ocular vasculature, such as retinal vasculitis. we hypothesize that there are differences in systemic microcirculation between pediatric uveitis patients and healthy pediatric controls.

the systemic microcirculation will be investigated through nailfold capillaroscopic (nfc) assessment with noninfectious uveitis and healthy pediatric controls. the nfc parameters are: capillary density (number of capillaries per mm), dilated capillaries (apex of \>20µm), avascular areas, the presence of microhemorrhages, and capillary morphology (normal, multiple crossings, tortuous, bushy, ramified, non-convex, or bizarre capillaries).

Eligibility criteria:
inclusion criteria: * patients with uveitis \< 18 years old exclusion criteria: * infectious uveitis * age \> 18 years old
tendyne european experience registry

Conditions: Mitral Regurgitation

Summary: tender is a multicenter, single-device, retrospective and prospective, observational study to assess safety and efficacy of the tendyne mitral valve system in a real-world population.

mitral regurgitation (mr) is a common disease and is associated with high morbidity and mortality if left untreated. due to age and comorbidities, patients are often ineligible for surgical repair or replacement. over the last years, transcatheter systems have been introduced as an alternative therapeutic approach. the tendyne mitral valve system (abbott vascular, roseville, minnesota) is a transcatheter transapical, self-expanding valve prosthesis for mitral valve replacement. a recent study has proven safety and feasibilty of the system, leading to commercial approvement (ce mark). however, data on real world experience with the system are not available. tender is a multicenter, single-device, retrospective and prospective, observational study. objectives of the study are 1) to assess early outcomes, including safety and efficacy, in patients treated with the tendyne mitral valve system for severe mr at 30 days, 2) to assess clinical outcomes in patients treated with the tendyne mitral valve system for severe mr at 1 year and 3 year follow-up, and 3) to identify echocardiographic and ct-based anatomic predictors associated with outcomes.

Eligibility criteria:
inclusion criteria: * patients treated with the tendyne mitral valve system for mitral valve disease in a commercial setting * patients providing written informed consent in compliance with the protocol, the ich-gcp and all national legal and regulatory requirements exclusion criteria: * patients not providing written informed consent

Keywords: mitral regurgitation tendyne transcatheter mitral valve replacement
oral amino acid nutrition to improve glucose excursions in pcos

Conditions: Polycystic Ovarian Syndrome; Obesity; Hepatic Steatosis

Summary: the investigators will measure hepatic glucose and fat metabolism in obese girls with polycystic ovarian syndrome (pcos) and hepatic steatosis (hs) after taking 4 weeks of an essential amino acid (eaa) supplement or placebo and test whether the eaa supplement can improve hepatic glucose metabolism in these girls.

girls with polycystic ovarian syndrome (pcos) and hepatic steatosis (hs) will complete a 12 week double-blinded placebo controlled cross-over study with 4 weeks each of an essential amino acid (eaa) supplement and placebo, and will complete metabolic studies after each intervention. there will be a 4 week wash out period in-between. the metabolic tests after each intervention (eaa/placebo) will include an oral sugar tolerance test (ostt) and an oral u-c13 glycerol tracer that is paired with nuclear magnetic resonance (nmr) isotopomer analysis of serum samples to describe flux through the hepatic pentose phosphate pathway, tricarboxylic acid (tca) cycle and fatty acid synthesis pathways in girls with pcos and hs. hepatic steatosis will be measured with magnetic resonance imaging (mri) and hepatic phosphate concentrations with magnetic resonance (mr) spectroscopy.

Eligibility criteria:
inclusion criteria: 1. females 2. ages 12-21 3. sedentary- less than 2 hours of moderate (jogging, swimming etc) exercise a week. 4. bmi equal or greater than the 90th percentile for age and gender 5. pcos per the most stringent nih criteria adapted for adolescents (irregular menses \>24 months post-menarche and clinical or biochemical hypertestosteronemia) 6. hs per fibroscan ultrasound, with cap score of \>225 (will be measured at screening visit) exclusion criteria: 1. use of medications known to affect insulin sensitivity: metformin, oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, hiv medications, hormonal contraception. dermal patch or vaginal ring contraception methods. 2. currently pregnant or breastfeeding women. development of pregnancy during the study period will necessitate withdrawal from the study. 3. severe illness requiring hospitalization within 60 days 4. diabetes, defined as hemoglobin a1c \> 6.4% 5. bmi percentile less than the 90th percentile for age and sex. weight \>325 lbs or \<84 lbs. 6. anemia, defined as hemoglobin \< 11 mg/dl 7. diagnosed major psychiatric or developmental disorder limiting informed consent 8. implanted metal devices that are not compatible with mri 9. use of blood pressure medications 10. known liver disease other than nafld or ast or alt \>125 iu/l

Keywords: hepatic de novo lipogenesis
improving glare and visual comfort for patients with visual impairment

Conditions: Photophobia; Visual Impairment; Low Vision

Summary: to assess the use of contact lenses with transitions technology to improve glare, light sensitivity and overall visual comfort in patients with visual impairment.

acuvue oasys contact lenses with transitions light intelligent technology can adapt to the amount of visible light in the environment, darkening the lenses in bright sunlight, and returning to regular tint in normal or dim environment. purpose of this study is to assess whether individuals with visual impairment may benefit from these lenses to minimize glare, light sensitivity symptoms and improve the overall visual comfort.

Eligibility criteria:
inclusion criteria: * ability to give informed consent * able to speak and read english * experience glare and light sensitivity that impacts patient's daily living activities * have confirmed diagnosis of ocular condition including but not limited to stargardt's, cone dystrophy, cone-rod dystrophy, albinism, retinitis pigmentosa and achromatopsia. * willing and able to wear the contact lenses as instructed exclusion criteria: * are pregnant, nursing or planning to become pregnant during the course of the study * have current/recent ocular infection, inflammation, surgery in the past 3 months that contraindicates contact lens wear
a study of dwj1248 in prevention of covid-19 infection after the exposure of sars-cov-2

Conditions: Covid19; SARS-COV-2 Infection

Summary: to evaluate the prevention of sars-cov-2 infection after administration of dwj1248 in person who contact from covid-19 confirmed patient compared to the placebo.


Eligibility criteria:
inclusion criteria: * adults over the age of 19 as of the signed date in written consent * subjects in self-quarantine who contact from covid-19 confirmed patient * subjects who have covid-19 negative rt-pcr result * subjects with no symptoms of covid-19 exclusion criteria: * subjects who cannot orally administer the investigational products * subjects who need administration of immunosuppressants * subjects who are allergic or sensitive to investigational products or its ingredients * subjects who have a history of drug and/or alcohol abuse within 12 months before screening * subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators
10-year results of open inguinal hernia repair

Conditions: Recurrence; Chronic Pain

Summary: the main goal of the research is to evaluate the long-term results of open anterior alloplasty of inguinal hernia, mainly the occurrence of recurrences. the secondary aim of the study is to clarify the incidence of chronic pain and foreign body sensation 10 years after inguinal hernia surgery. patients who meet the criteria for inclusion in the study are invited to an appointment, where a questionnaire is filled out, an clinical examination and an ultrasound examination are performed.


Eligibility criteria:
inclusion criteria: * primary inguinal hernia operated between 2008-2013 at the tartu university hospital * elective surgery * age at least 18 years old at the time of the operation * ability to understand the guidelines and willing to participate in the study exclusion criteria: * recurrent hernia * strangulated hernia * age under 18 years at the time of surgery * does not agree to participate in the study * does not understand the guidelines. regarding the last exclusion criterion: since it is an assessment of the remote results of the treatment and probably relatively many of the subjects are very elderly, it may happen that when contacting the patient by phone it turns out that the patient is no longer adequate to make a decision about participating in the study or to answer questions (experienced cerebral infarction, dementia, etc. .) - in this case, the patient is not invited to the appointment.
tissue sodium in autoimmune disease

Conditions: Systemic Lupus Erythematosus

Summary: this pilot study will test the hypothesis that a low sodium diet will decrease sodium (23na) magnetic resonance imaging-determined skin sodium concentrations in patients with systemic lupus erythematosus (sle) and improve blood pressure and inflammation

this pilot study will test the hypothesis that a low sodium diet will decrease 23na magnetic resonance imaging-determined skin sodium concentrations in patients with sle and improve blood pressure and inflammation. investigators plan to enroll 21 participants who will be randomized to low salt or high salt diet. participants will eat the first diet for 28 days, and after a 2 week washout, participants will eat the second diet (whichever the participant was not randomized to for the first phase). participant will know what diet participant is on, study coordinator who does the assessment will be blinded to diet.

Eligibility criteria:
inclusion criteria: * male and female patients 18 and over * meets 2012 international criteria for the diagnosis of sle * have stable disease activity as evidenced by no significant change in immunomodulating therapy in last month * provide written informed consent exclusion criteria: * pregnancy * receiving dialysis * organ or bone marrow transplant * uncontrolled hypertension, bp\> 160/100 mm hg at screening * severe edema as judged by investigator * diabetes mellitus requiring drug therapy * major surgery within the previous 3 months * severe co-morbid conditions such as active cancer likely to compromise study participation * unwillingness or other inability to cooperate * conditions that alter sodium homeostasis substantially including heart failure, clinically evident liver disease, clinically evident renal dysfunction (creatinine clearance \ 2+ proteinuria, or being treated for lupus nephritis
intensive care unit and secondary and primary immune deficiency

Conditions: Primary Immune Deficiency Disorder

Summary: primary immune deficiencies (pid) are characterized by a failure of the immune system that is not explained by any infectious, neoplastic, or iatrogenic cause. in 2015, more than 300 different inherited rare disorders were described. the occurrence of pid in adult is rare and diagnosis may be supported by the 6 esid signs for adult. however these warnings signs are based only on expert recommendations and do not include comprehensive symptoms of pids. recurrent infections, more aggressive, are the most common mode of revelation of the pid. less frequently, autoimmune manifestation, solid tumor, lymphoproliferation tumor, chronic granulomatosis or hemophagocytic lymphohistiocytosis syndrome (hls) may also revealed a pid. the objective of this study was to evaluate the occurrence of unknown pid in adult admitted in critical care unit and to determinate if the investigation of pid in patients with severe infections or hls should be routinely performed in mciu.


Eligibility criteria:
inclusion criteria: * aged 18-65 * hospitalized in medical intensive care unit for : * severe infection without pathogen identification * severe infection due to encapsuled pathogen * opportunistic infections or unusual pathogen * idiopathic hemophagocytic syndrome exclusion criteria: * primary immunodeficiency already known * secondary immunodeficiency already known (hiv, cancer, immunosuppressive or immunomodulatory treatment, nephrotic syndrome, protein-losing enteropathy, severe malnutrition before admission, cirrhosis with hepatic failure, sickle cell disease, splenectomy and moderate chronic renal failure (clearance between 30 and 59 m² min/1.73 ml) * local-regional factors which can be responsible for infections (history of ear, nose and throat surgery or neurosurgery, history of fracture of the skull base, cystic fibrosis, chronic respiratory insufficient)

Keywords: primary immunodeficiency secondary immunodeficiency intensive care unit infection adult
glucocorticoid in treatment of adult idiopathic nephrotic syndrome：a prospective observational study

Conditions: Nephrotic Syndrome，Idiopathic

Summary: this study is to assess the efficacy and safety of 8-weeks full-dose induction protocol (prednisone 1mg/kg, maximum 60mg/day) and protracted tapering protocol in the treatment of adult idiopathic nephrotic syndrome.

in full-dose induction period, patients scheme to visit at the 4th and 8th week, and in protracted tapering period at 10th , 22nd, 42nd and 66th week. if the patients reach complete remission within 4 weeks, prednisone may be decreased at the 6th week, otherwise keep on the course to the 8th week. all patients reach complete remission will shift to protracted tapering period and follow up until prednisone withdrawal, except the cases that relapse and drop out the study. if proteinuria reappears in someone, angiotensin-converting enzyme inhibitor（acei） or angiotensin receptor blocker（arb） will be considered combination, on the premise of the blood pressure is affordable.

Eligibility criteria:
inclusion criteria: * patients who signed written informed consent form * age between 18-65 years, female or male * patients with diagnosis of nephrotic syndrome ( proteinuria ≥3.5 g/24h, and serum albumin ≤30g/l ), * pathological diagnosis with minimal change disease (mcd), focal segmental glomerulosclerosis (fsgs) and podocyte disease * serum creatinine \< 3mg/dl ( 265.2umol/l), estimated glomerular filtration rate(egfr) no less than 30 ml/min.1.73 m2 exclusion criteria: * patients who didn't sign written informed consent form * patients who have received full-dose prednisone treatment for more than 2 weeks, or pulsed methylprednisolone (\>7.5mg/kg.day) within 2 weeks * patients who have taken immunosuppressants within 3 months, as cyclosporine a, tacrolimus, mycophenolate mofetil, cyclophosphamide, or leflunomide etc. * patients who have impaired liver function, with alanine aminotransferase(alt) or aspartate aminotransferase(ast) twice more than the normal upper limit, or who have viral hepatitis b with hepatitis b e antigen(hbeag) positive or hepatitis b virus dna (hbv-dna) reduplicative * patients who have contraindications to glucocorticoid, for example diabetes, obesity (bmi\>28kg/m2 before disease onset), femoral head necrosis, or active infection. * patients who have family history of kidney disease * patients who have definite secondary facts of this disease.

Keywords: prednisone idiopathic nephrotic syndrome prospective
clinical investigation of the safety and effectiveness of an investigational model of the tecnis® intraocular lens

Conditions: Cataract; Corneal Astigmatism

Summary: this study will be a prospective, multicenter, bilateral, comparative, three-way masked (sponsor, subject and evaluator), randomized clinical investigation conducted at up to 15 sites. up to 300 subjects will be enrolled to achieve approximately 270 bilaterally implanted subjects, resulting in approximately 244 evaluable subjects (122 per lens group) at 6 months. after informed consent is obtained and confirmation that all eligibility criteria are met, the eye(s) may be treated according to randomization. after signing the informed consent form, subjects meeting all eligibility criteria will be randomized in a masked fashion to a treatment group: either the investigational iol model zfr00v or the control iol model zcb00. prior to randomization, the investigator will choose which eye to operate on first for each subject at his/her discretion based on his/her standard clinical practice (e.g., the eye with the worse cataract, poorer best corrected distance vision and/or more severe optical/visual complaints). all subjects are intended to have bilateral cataract surgery with the second eye surgery occurring after the 1-week postoperative exam for the first eye, but no more than 30 days after the first eye surgery. all subjects will be examined through 6 months postoperatively according to the visit schedule


Eligibility criteria:
inclusion criteria: * be at least 22 years old * have cataracts in both eyes * sign the written informed consent * be willing and able to comply with examination procedures * understand, read and write english to complete informed consent and questionnaires * be available for study follow-up visits exclusion criteria: * currently participating in any other clinical study or have participated in a clinical study during the last 60 days * have a certain disease/illness such as poorly-controlled diabetes * have certain ocular conditions such as uncontrolled glaucoma * is taking medication that may affect vision * subject is pregnant, plan to become pregnant during the study, or is breastfeeding
mri-markers to monitor small vessel disease dynamics in the prognosis of small vessel disease-associated, cerebrovascular events

Conditions: Intracerebral Hemorrhage; CAA - Cerebral Amyloid Angiopathy; Cerebral Small Vessel Diseases

Summary: this is a nested cohort study in the pro-svd cohort. small vessel disease is a chronic disease and is thought to progress over time. mri is the gold standard to diagnose small vessel disease, but data on mri-visible disease progression are scarce. complications of small vessel disease as well as location pattern, distribution and severity of these mri small vessel disease markers differ according to the underlying phenotype. the primary aim of this project is to investigate individual small vessel disease burden progression detected by mri in survivors or intracerebral hemorrhage.


Eligibility criteria:
for patients with intracerebral hemorrhage inclusion criteria: * patient participating in the pro-svd cohort * symptomatic intracranial hemorrhage * written informed consent provided by patient or next-of-kin * no contraindications against mri exclusion criteria: * patient unsuitable for mri follow-ups (e.g. claustrophobia) * patients unlikely to attend 1-year follow-up for healthy controls inclusion criteria: * clinically healthy person ≥ 55 years * written informed consent provided by the healthy control * no contraindications against mri exclusion criteria: * known or suspected cerebral small vessel diseases or presence of concurrent diseases potentially mimicking small vessel disease (e.g. multiple sclerosis, previous heart surgery etc.) * pre-existing dementia, cognitive decline or disorder of the central nervous system.

Keywords: intracerebral hemorrhage ischemic stroke cerebral amyloid angiopathy hypertensive deep perforator arteriopathy 7 tesla-mri cerebral small vessel disease ultra high-field mri